Cargando…
In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935601/ https://www.ncbi.nlm.nih.gov/pubmed/29728790 http://dx.doi.org/10.1186/s40635-018-0177-2 |
_version_ | 1783320298167205888 |
---|---|
author | Malard, Benjamin Lambert, Corine Kellum, John A. |
author_facet | Malard, Benjamin Lambert, Corine Kellum, John A. |
author_sort | Malard, Benjamin |
collection | PubMed |
description | BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-associated mediators and endotoxins. METHODS: In vitro hemoperfusion was performed using oXiris(®), CytoSorb(®), and Toraymyxin(®). Heparinized human plasma from healthy volunteers was pre-incubated with pathologic quantities of inflammatory mediators and filtered in a closed-loop circulation model for 2 h. For each device, the removal of 27 inflammatory mediators was measured over time. Endotoxin removal mediated by oXiris and Toraymyxin was assessed using hemoperfusion over 6 h. RESULTS: Endotoxin (lipopolysaccharide) removal was most rapid with Toraymyxin; mean adsorptive clearance over the first 30 min was ~ 20 ml/min vs ~ 8 ml/min with oXiris (p < 0.05). There was minimal endotoxin removal with CytoSorb (1 ml/min). At 120 min, there was no significant difference between the endotoxin removal rates using oXiris (mean ± standard deviation, 68.0 ± 4.4%) and Toraymyxin (83.4 ± 3.8%); both were significantly higher vs CytoSorb (− 6.3 ± 4.9%; p < 0.05). Total removal with oXiris was 6.9 μg vs 9.7 μg for Toraymyxin, where the total lipopolysaccharide quantity introduced was approximately 15.8 μg. Removal rates of pro-/anti-inflammatory cytokines and other inflammatory mediators were similar between oXiris and CytoSorb and were higher with CytoSorb and oXiris vs Toraymyxin. Granulocyte colony-stimulating factor was only effectively adsorbed by CytoSorb (99.4%). Differences were detected between the adsorption mechanism of the devices; binding to oXiris was mainly ionic, while CytoSorb was hydrophobic. No specific protein adsorption was found qualitatively with Toraymyxin. CONCLUSIONS: Adsorption rate kinetics varied for individual inflammatory mediators using the three blood purification devices. Mechanisms of adsorption differed between the devices. oXiris was the only device tested that showed both endotoxin and cytokine removal. oXiris showed similar endotoxin adsorption to Toraymyxin and similar adsorption to CytoSorb for the removal of other inflammatory mediators. Differences in device removal capacities could enable treatment to be more tailored to patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40635-018-0177-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5935601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59356012018-05-09 In vitro comparison of the adsorption of inflammatory mediators by blood purification devices Malard, Benjamin Lambert, Corine Kellum, John A. Intensive Care Med Exp Research BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-associated mediators and endotoxins. METHODS: In vitro hemoperfusion was performed using oXiris(®), CytoSorb(®), and Toraymyxin(®). Heparinized human plasma from healthy volunteers was pre-incubated with pathologic quantities of inflammatory mediators and filtered in a closed-loop circulation model for 2 h. For each device, the removal of 27 inflammatory mediators was measured over time. Endotoxin removal mediated by oXiris and Toraymyxin was assessed using hemoperfusion over 6 h. RESULTS: Endotoxin (lipopolysaccharide) removal was most rapid with Toraymyxin; mean adsorptive clearance over the first 30 min was ~ 20 ml/min vs ~ 8 ml/min with oXiris (p < 0.05). There was minimal endotoxin removal with CytoSorb (1 ml/min). At 120 min, there was no significant difference between the endotoxin removal rates using oXiris (mean ± standard deviation, 68.0 ± 4.4%) and Toraymyxin (83.4 ± 3.8%); both were significantly higher vs CytoSorb (− 6.3 ± 4.9%; p < 0.05). Total removal with oXiris was 6.9 μg vs 9.7 μg for Toraymyxin, where the total lipopolysaccharide quantity introduced was approximately 15.8 μg. Removal rates of pro-/anti-inflammatory cytokines and other inflammatory mediators were similar between oXiris and CytoSorb and were higher with CytoSorb and oXiris vs Toraymyxin. Granulocyte colony-stimulating factor was only effectively adsorbed by CytoSorb (99.4%). Differences were detected between the adsorption mechanism of the devices; binding to oXiris was mainly ionic, while CytoSorb was hydrophobic. No specific protein adsorption was found qualitatively with Toraymyxin. CONCLUSIONS: Adsorption rate kinetics varied for individual inflammatory mediators using the three blood purification devices. Mechanisms of adsorption differed between the devices. oXiris was the only device tested that showed both endotoxin and cytokine removal. oXiris showed similar endotoxin adsorption to Toraymyxin and similar adsorption to CytoSorb for the removal of other inflammatory mediators. Differences in device removal capacities could enable treatment to be more tailored to patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40635-018-0177-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-04 /pmc/articles/PMC5935601/ /pubmed/29728790 http://dx.doi.org/10.1186/s40635-018-0177-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Malard, Benjamin Lambert, Corine Kellum, John A. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title | In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title_full | In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title_fullStr | In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title_full_unstemmed | In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title_short | In vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
title_sort | in vitro comparison of the adsorption of inflammatory mediators by blood purification devices |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935601/ https://www.ncbi.nlm.nih.gov/pubmed/29728790 http://dx.doi.org/10.1186/s40635-018-0177-2 |
work_keys_str_mv | AT malardbenjamin invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices AT lambertcorine invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices AT kellumjohna invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices |